Long-term follow-up. (A) Duration of continuous remission in patients who are at ≥2 years after CART infusion. Each bar represents a patient, identified by a subject ID. The length of each bar represents number of years in remission post-CART therapy. Patients are color categorized by the CART for which they received. Fourteen (56%) received CD19 CARTs, 6 (24%) received CD22 CARTs, and 5 (20%) received CD19/22 CARTs. The circles along the bars indicate when patients received HCT (median time, 1.8 months; range 1.4-3.2). No patients experienced a relapse of B-ALL. X indicates death related to cholangiocarcinoma. (B) Late-effects of CART therapy. This bar graph depicts the prevalent late-effects of CART therapy for patients in the primary cohort (n = 25). The graph represents the FDA parameters for gene therapy LTFU and the percentage of patients who developed each disorder, along with the prevalence of conditions such as GVHD, nonmalignant tumors/growths, and endocrine disorders. GVHD, graft-versus-host disease.